
    
      This is a Phase 2 study to evaluate the efficacy and safety of a single subretinal
      administration of CNTO 2476 compared with the untreated control group, as well as to assess
      the safety and usability profile of the procedure and the device for cell therapy delivery in
      participants with visual acuity impairment associated with Geographic Atrophy (GA) secondary
      to Age Related Macular Degeneration (AMD). The duration of participation in the study for
      each participant is approximately 3 years. Efficacy will be evaluated at 6 month, 12 months
      and every 6 month thereafter. Participant's safety will be monitored throughout the study.
    
  